#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	3290	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2407	402.2	1	SNP	n	C1184T	1	C1184T	SNP	1184	1184	C	1539	1539	T	483	T	425	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	3290	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2407	402.2	0	.	n	.	0	C1450T	SNP	1450	1450	C	1805	1805	T	471	T	425	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4848	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3888	373.9	0	.	n	.	0	C993T	SNP	993	993	C	1513	1513	T	403	T,C	352,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4848	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3888	373.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1857	1857	A	420	A,G	367,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4848	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3888	373.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2491	2491	C	473	C,G	406,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4848	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3888	373.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2565	2565	A	474	A,G	408,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4848	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3888	373.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	3117	3117	C	456	C,A	386,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
blaTEM.WHO_M_pConjugative_00003	blaTEM.WHO_M_pConjugative_00003	1	0	27	33500	blaTEM	861	861	100.0	blaTEM.l6.c4.ctg.1	1759	5676.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Betalactam resistance
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	498	folP	855	855	100.0	folP.l15.c4.ctg.1	1768	84.2	1	SNP	p	R229S	1	.	.	685	687	AGC	1144	1146	AGC	117;117;117	A,G;G;C	98,1;100;99	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1044	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3642	85.8	1	SNP	p	S91F	0	.	.	271	273	TCC	724	726	TCC	97;98;98	T,C;C;C	84,1;86;88	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1044	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3642	85.8	1	SNP	p	D95N	0	.	.	283	285	GAC	736	738	GAC	100;100;99	G;A;C	87;87;86	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1044	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3642	85.8	1	SNP	p	D95G	0	.	.	283	285	GAC	736	738	GAC	100;100;99	G;A;C	87;87;86	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	446	mtrR	633	633	100.0	mtrR.l6.c4.ctg.1	1583	84.4	1	SNP	p	G45D	0	.	.	133	135	GGC	601	603	GGC	137;137;138	G;G;C	114;116;116	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	290	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1274	68.2	0	.	n	.	0	A197.	DEL	197	197	A	687	687	A	127	A	112	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	1032	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3231	95.9	1	SNP	p	D86N	0	.	.	256	258	GAC	703	705	GAC	120;121;120	G;A,G;C	100;99,1;99	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	1032	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3231	95.9	1	SNP	p	S87W	0	.	.	259	261	AGT	706	708	AGT	118;120;120	A;G;T	100;102;101	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	1032	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3231	95.9	1	SNP	p	S87I	0	.	.	259	261	AGT	706	708	AGT	118;120;120	A;G;T	100;102;101	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	1032	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3231	95.9	1	SNP	p	S87R	0	.	.	259	261	AGT	706	708	AGT	118;120;120	A;G;T	100;102;101	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	1032	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3231	95.9	1	SNP	p	S88P	0	.	.	262	264	TCC	709	711	TCC	121;122;121	T;C;C	100;102;101	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	920	parE	1986	1986	100.0	parE.l6.c4.ctg.1	2936	94.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1734	1736	GGC	105;105;105	G;G;C	94;91;92	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	760	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2585	88.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1294	1296	GCA	118;118;118	G;C;A	108;105;108	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	760	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2585	88.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1297	1299	ATC	117;116;117	A;T;C	107;104;107	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	760	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2585	88.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1309	1311	GTG	119;119;119	G;T;G	107;104;107	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	760	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2585	88.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1309	1311	GTG	119;119;119	G;T;G	107;104;107	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	760	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2585	88.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1813	1815	ACC	83;83;81	A,G;C;C,A	72,1;74;71,1	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	760	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2585	88.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1867	1869	GCG	83;82;82	G,T;C;G	71,1;69;69	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	760	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2585	88.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1867	1869	GCG	83;82;82	G,T;C;G	71,1;69;69	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	760	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2585	88.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1990	1992	GGC	86;88;88	G;G;C	72;75;75	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	760	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2585	88.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1999	2001	GGC	89;89;89	G;G;C	75;74;78	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	760	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2585	88.0	1	SNP	p	P552S	1	.	.	1654	1656	TCG	2017	2019	TCG	82;83;84	T,A;C,T;G	73,1;75,1;75	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1052	ponA	2397	2397	100.0	ponA.l15.c17.ctg.1	3358	93.6	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1813	1815	CCG	106;107;107	C;C,A;G	89;90,1;89	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	548	porA	1146	1146	99.65	porA.l6.c4.ctg.1	2042	80.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	673	673	C	118	C	103	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	70	porB1a	984	297	90.37	porB1a.l15.c4.ctg.1	1514	13.0	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1240	1242	AAT	12;11;11	A;A;T	11;10;10	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	70	porB1a	984	297	90.37	porB1a.l15.c4.ctg.1	1514	13.0	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1243	1245	AAT	11;11;11	A;A;T	10;10;10	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	70	porB1a	984	297	90.37	porB1a.l15.c4.ctg.1	1514	13.0	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1267	1269	GCA	10;10;10	G;C;A	9;9;9	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	70	porB1a	984	297	90.37	porB1a.l15.c4.ctg.1	1514	13.0	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1290	1292	GTA	9;8;8	G;T;A	9;8;7	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	70	porB1a	984	297	90.37	porB1a.l15.c4.ctg.1	1514	13.0	0	.	p	.	0	S236N	NONSYN	706	708	AGC	1296	1298	AAC	8;8;8	A;A;C	7;7;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	70	porB1a	984	297	90.37	porB1a.l15.c4.ctg.1	1514	13.0	0	.	p	.	0	.	MULTIPLE	709	711	AAC	1300	1304	TGGCG	8;8;8;8;8	T;G;G;C;G	8;8;8;8;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	70	porB1a	984	297	90.37	porB1a.l15.c4.ctg.1	1514	13.0	0	.	p	.	0	D238A	NONSYN	712	714	GAT	1306	1308	GCT	8;8;8	G;C;T	8;8;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	70	porB1a	984	297	90.37	porB1a.l15.c4.ctg.1	1514	13.0	0	.	p	.	0	A251V	NONSYN	751	753	GCG	1345	1347	GTA	8;8;8	G;T;A	8;8;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	70	porB1a	984	297	90.37	porB1a.l15.c4.ctg.1	1514	13.0	0	.	p	.	0	S271T	NONSYN	811	813	TCG	1405	1407	ACT	8;8;8	A;C;T	8;8;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	70	porB1a	984	297	90.37	porB1a.l15.c4.ctg.1	1514	13.0	0	.	p	.	0	Y273D	NONSYN	817	819	TAT	1411	1413	GAT	8;8;8	G;A;T	7;6;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	70	porB1a	984	297	90.37	porB1a.l15.c4.ctg.1	1514	13.0	0	.	p	.	0	D276N	NONSYN	826	828	GAT	1420	1422	AAC	8;8;8	A;A;C	8;7;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	70	porB1a	984	297	90.37	porB1a.l15.c4.ctg.1	1514	13.0	0	.	p	.	0	N277H	NONSYN	829	831	AAC	1423	1425	CAC	8;8;8	C;A;C	7;7;8	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	27	590	porB1b	1041	1041	100.0	porB1b.l15.c4.ctg.1	2015	87.8	1	SNP	p	G120K	1	.	.	358	360	AAG	895	897	AAG	129;128;128	A;A;G	107;108;107	porB1b.WHO_O_01976:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	27	590	porB1b	1041	1041	100.0	porB1b.l15.c4.ctg.1	2015	87.8	1	SNP	p	A121D	1	.	.	361	363	GAC	898	900	GAC	129;129;129	G;A;C	108;106;107	porB1b.WHO_O_01976:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	27	590	porB1b	1041	1041	100.0	porB1b.l15.c4.ctg.1	2015	87.8	1	SNP	p	D121N	0	.	.	361	363	GAC	898	900	GAC	129;129;129	G;A;C	108;106;107	porB1b.WHO_O_01976:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	2124	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5234	121.5	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2160	2162	CAT	170;170;170	C;A;T,A	142;142;143,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	300	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1363	66.0	1	SNP	p	V57M	1	.	.	169	171	ATG	712	714	ATG	111;111;113	A;T;G	99;101;101	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
